Atenolol versus losartan in children and young adults with Marfan's syndrome

New England Journal of Medicine

Volumn 371, Issue 22, 2014, Pages 2061-2071

  Lacro, Ronald V ^a   Dietz, Harry C ^b   Sleeper, Lynn A ^c   Yetman, Anji T ^d   Bradley, Timothy J ^e   Colan, Steven D ^a,c   Pearson, Gail D ^f   Selamet Tierney, E Seda ^a   Levine, Jami C ^a   Atz, Andrew M ^g   Benson, D Woodrow ^h   Braverman, Alan C ⁱ   Chen, Shan ^c   De Backer, Julie ^j   Gelb, Bruce D ^k   Grossfeld, Paul D ⁿ   Klein, Gloria L ^c   Lai, Wyman W ^l   Liou, Aimee ^o   Loeys, Bart L ^j   Markham, Larry W ^p   Olson, Aaron K ^q   Paridon, Stephen M ^r   Pemberton, Victoria L ^f   Pierpont, Mary Ella ^t   Pyeritz, Reed E ^s   Radojewski, Elizabeth ^e   Roman, Mary J ^m   Sharkey, Angela M ⁱ   Stylianou, Mario P ^f   Wechsler, Stephanie Burns ^u   Young, Luciana T ^v   Mahony, Lynn ^w   more..

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW ENGLAND RESEARCH INSTITUTES   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h Children's Medical Center   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l Children's Hospital of New York   (United States)

^m WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o Texas Children's Hospital   (United States)

^p VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q SEATTLE CHILDREN S HOSPITAL   (United States)

^r CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^s UNIVERSITY OF PENNSYLVANIA   (United States)

^t CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^u DUKE UNIVERSITY MEDICAL CENTER   (United States)

^v Ann and Robert H Lurie Children's Hospital of Chicago   (United States)

^w UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; LOSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGE DISTRIBUTION; AORTA DISEASE; AORTA DISSECTION; AORTA VALVE REGURGITATION; AORTIC ROOT DIAMETER; AORTIC ROOT DILATATION; AORTIC ROOT ENLARGEMENT; AORTIC ROOT SURGERY; AORTIC ROOT Z SCORE; ARTICLE; BLOOD VESSEL DIAMETER; BLOOD VESSEL PARAMETERS; BODY SURFACE; CARDIOVASCULAR MORTALITY; CHILD; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART RATE; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MARFAN SYNDROME; MEDICATION COMPLIANCE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT; YOUNG ADULT; AORTA; AORTIC ANEURYSM; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; STATISTICAL MODEL; SURGERY; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; AORTA; AORTIC ANEURYSM; AORTIC VALVE INSUFFICIENCY; ATENOLOL; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; LINEAR MODELS; LOSARTAN; MALE; MARFAN SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84915756479     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1404731     Document Type: Article

References (28)

1. Judge DP, Dietz HC. Marfan's syndrome. Lancet 2005;366:1965-76.
2. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994;330:1335-41.
3. Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. Circulation 2005;111(11):e150-e157.
4. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991;352:337-9.
5. Dietz HC. TGF-beta in the pathogenesis and prevention of disease: a matter of aneurysmic proportions. J Clin Invest 2010;120:403-7.
6. Lindsay ME, Dietz HC. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature 2011;473:308-16.
7. Everett AD, Tufro-McReddie A, Fisher A, Gomez RA. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension 1994;23:587-92.
8. Fukuda N, Hu WY, Kubo A, et al. Angiotensin II upregulates transforming growth factor-beta type I receptor on rat vascular smooth muscle cells. Am J Hypertens 2000;13:191-8.
9. Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, Kohno N. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am J Physiol Renal Physiol 2004;286:F278-F287.
10. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312:117-21.
11. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC III. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008;358: 2787-95.
12. Pees C, Laccone F, Hagl M, Debrauwer V, Moser E, Michel-Behnke I. Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome. Am J Cardiol 2013;112: 1477-83.
13. Lacro RV, Dietz HC, Wruck LM, et al. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J 2007; 154:624-31.
14. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996;62:417-26.
15. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005;37:275-81.
16. Greally MT. Shprintzen-Goldberg syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews. Seattle: University of Washington, 2006 (http://www.ncbi.nlm.nih.gov/books/NBK1277).
17. Erkula G, Jones KB, Sponseller PD, Dietz HC, Pyeritz RE. Growth and maturation in Marfan syndrome. Am J Med Genet 2002;109:100-15.
18. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis 1974;27:365-75.
19. Selamet Tierney ES, Levine JC, Chen S, et al. Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome. J Am Soc Echocardiogr 2013;26:657-66.
20. Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. Hoboken, NJ: John Wiley, 2004.
21. Lacro RV, Guey LT, Dietz HC, et al. Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy. Am Heart J 2013;165:828-35.
22. Chiu HH, Wu MH, Wang JK, et al. Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin Proc 2013;88:271-6.
23. Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J 2013;34:3491-500.
24. Gambarin FI, Favalli V, Serio A, et al. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. J Cardiovasc Med (Hagerstown) 2009;10:354-62.
25. Detaint D, Aegerter P, Tubach F, et al. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. Arch Cardiovasc Dis 2010;103:317-25.
26. Forteza A, Evangelista A, Sánchez V, et al. Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome. Rev Esp Cardiol 2011;64:492-8. (In Spanish.)
27. Möberg K, De Nobele S, Devos D, et al. The Ghent Marfan Trial - a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers. Int J Cardiol 2012;157: 354-8.
28. Mullen MJ, Flather MD, Jin XY, et al. A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol. Trials 2013;14:408.